Literature DB >> 10394407

Three dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for prostate carcinoma: early results.

S Wachter1, N Gerstner, G Goldner, K Dieckmann, A Colotto, R Pötter.   

Abstract

BACKGROUND: The therapeutic outcome and toxicity of 3-D conformal photon external beam therapy of prostate cancer is well documented in the literature. Progress is still in work for optimization of treatment strategies by risk-adapted dose escalation studies to improve local tumor control without increase of radiation side effects. PATIENTS AND METHODS: We present our experience of 291 patients treated between January 1994 and August 1997 with a 3-D planned four-field box technique and a central dose of 66 Gy. Biochemical response of patients with radiotherapy alone (group 1, n = 72 pts.) has been analyzed in detail. Acute radiation side effects are given for all patients (n = 291), late radiation side effects are given for patients treated between Jan 1994 and Jan 1996 with a median follow-up of 22 months (n = 115 pts.).
RESULTS: We have observed a biochemical response (nadir PSA < 1 after 12 months, < 2 after 6 months) for patients treated with radiotherapy alone without hormone manipulation in 67%. Incidence of late rectal and bladder morbidity (grade 2 and 3) was 9.4% and 4%, respectively.
CONCLUSION: Compared to other reports our results indicate a high rate of local tumor control (early biochemical response) and a low rate of late morbidity. Nevertheless, we will start a risk-adapted dose escalation study up to 74 Gy for unfavorable subgroups (G2-3, Gleason Score > 7, PSA > 10) to improve treatment outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10394407     DOI: 10.1007/bf03038898

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  10 in total

1.  Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.

Authors:  N Fukunaga-Johnson; H M Sandler; P W McLaughlin; M S Strawderman; K H Grijalva; K E Kish; A S Lichter
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

2.  Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment.

Authors:  D M Tait; A E Nahum; L C Meyer; M Law; D P Dearnaley; A Horwich; W P Mayles; J R Yarnold
Journal:  Radiother Oncol       Date:  1997-02       Impact factor: 6.280

3.  [Planned 3-dimensional low-volume conformal irradiation of a local prostatic carcinoma].

Authors:  S Wachter; N Gerstner; K Dieckmann; M Stampfer; R Hawliczek; R Pötter
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

4.  Late GI and GU complications in the treatment of prostate cancer.

Authors:  T E Schultheiss; W R Lee; M A Hunt; A L Hanlon; R S Peter; G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-01       Impact factor: 7.038

5.  Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML.

Authors:  G E Hanks; W R Lee; A L Hanlon; M Hunt; E Kaplan; B E Epstein; B Movsas; T E Schultheiss
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-07-15       Impact factor: 7.038

6.  Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study.

Authors:  G E Hanks; T E Schultheiss; A L Hanlon; M Hunt; W R Lee; B E Epstein; L R Coia
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-02-01       Impact factor: 7.038

7.  Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer.

Authors:  G E Hanks; T E Schultheiss; M A Hunt; B Epstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-01-01       Impact factor: 7.038

8.  Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity.

Authors:  E M Soffen; G E Hanks; M A Hunt; B E Epstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

9.  Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.

Authors:  G K Zagars
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

10.  Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.

Authors:  V S Kavadi; G K Zagars; A Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-09-30       Impact factor: 7.038

  10 in total
  1 in total

1.  Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements.

Authors:  Matthias Moll; Harald Herrmann; Alexandru Zaharie; Gregor Goldner
Journal:  Radiol Oncol       Date:  2022-08-14       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.